Results 221 to 230 of about 82,077 (257)

Recombinant viral vectors: Cancer vaccines

Advanced Drug Delivery Reviews, 2006
To date cancer vaccines have yet to show efficacy in a phase III trial. However, the clinical benefit seen with monoclonal antibody mediated therapies (e.g., Herceptin) has provided proof of principle that immune responses directed against tumour-associated antigens could have therapeutic potential.
Richard, Harrop, Justin, John, Miles W, Carroll   +2 more
openaire   +2 more sources

Recombinant vaccines against ovine footrot

Immunology & Cell Biology, 1993
SummaryFor the past 20 years footrot vaccines have evolved from simple bacterins to highly specific recombinant DNA (rDNA) fimbrial vaccines. The development of these vaccines has left a trail of discoveries, challenges and solutions; these processes continue as we move closer to understanding the requirements of a footrot vaccine.
T J, O'Meara, J R, Egerton, H W, Raadsma
openaire   +2 more sources

Recombinant Vaccine Production: Production of a Recombinant CCHF MVA Vaccine

One of the key interventions against infection is immunization, including an increasing focus on development of vaccines against pathogenic bunyaviruses. Whilst different vaccine development approaches exist, recombinant viral vaccines have a strong safety record, are rapid to produce, are cost-effective, and have been demonstrated to be rolled out in ...
Emma, Kennedy, Roger, Hewson, Stuart, Dowall   +2 more
openaire   +2 more sources

Recombinant Salmonella vaccines for biodefence

Vaccine, 2006
There is a requirement for vaccines to protect against pathogens that may be misused for bioterrorism or biowarfare purposes. In particular, biodefence vaccines are required that may be used for safe and easy immunisation of populations and that can rapidly induce mucosal immunity to provide protection at the lung surface against a range of airborne ...
Helen S, Atkins, Margaret, Morton, Kate F, Griffin, Margaret G M, Stokes, James P, Nataro, Richard W, Titball   +5 more
openaire   +2 more sources

Recombinant Proteins in Vaccine Development

2003
The outer membrane of Neisseria meningitidis contains a variety of proteins with the potential for inclusion in new meningococcal vaccines (1). Studies on the vaccine potential of these proteins would be facilitated by the production of pure recombinant protein, free from other components of the Neisseria outer membrane.
M, Christodoulides, K A, Jolley, J E, Heckels   +2 more
openaire   +2 more sources

Recombinant BCG vaccines

Vaccine, 2001
N, Ohara, T, Yamada
openaire   +2 more sources

Mycobacterium recombinant vaccines.

La Tunisie medicale, 2001
Intracellular diseases are difficult to treat and constitute a major problem for modern medicine. In this type of diseases, a TH-1 immune response favors protection, while a TH-2 response is detrimental to the host. Current vaccines are using antigens to initiate an immune response regardless of its nature and its mechanism.
A H, Labidi, R C, Estes, H L, David, A P, Bollon   +3 more
openaire   +1 more source

The role of vaccines in combatting antimicrobial resistance

Nature Reviews Microbiology, 2021
Francesca Micoli, Rino Rappuoli
exaly  

Next-generation influenza vaccines: opportunities and challenges

Nature Reviews Drug Discovery, 2020
Chih-Jen Wei, John R Mascola, Gary J Nabel   +2 more
exaly  

Advances in the development of influenza virus vaccines

Nature Reviews Drug Discovery, 2015
Florian H Krammer, Peter Palese
exaly